219 related articles for article (PubMed ID: 38091201)
21. Targeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors.
Tsurutani J; Iwata H; Krop I; Jänne PA; Doi T; Takahashi S; Park H; Redfern C; Tamura K; Wise-Draper TM; Saito K; Sugihara M; Singh J; Jikoh T; Gallant G; Li BT
Cancer Discov; 2020 May; 10(5):688-701. PubMed ID: 32213540
[TBL] [Abstract][Full Text] [Related]
22. Neoadjuvant trastuzumab deruxtecan (T-DXd) with response-directed definitive therapy in early stage HER2-positive breast cancer: a phase II study protocol (SHAMROCK study).
Dowling GP; Toomey S; Bredin P; Parker I; Mulroe E; Marron J; McLoughlin O; Teiserskiene A; Power C; O'Shea AM; Greally M; Morris PG; Duke D; Hill ADK; Hennessy BT
BMC Cancer; 2024 Jan; 24(1):91. PubMed ID: 38233810
[TBL] [Abstract][Full Text] [Related]
23. Empower the Potential of Trastuzumab Deruxtecan with Novel Combinations.
Rolfo C; Del Re M; Russo A
Clin Cancer Res; 2023 Nov; 29(21):4317-4319. PubMed ID: 37656059
[TBL] [Abstract][Full Text] [Related]
24. Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study.
Shitara K; Iwata H; Takahashi S; Tamura K; Park H; Modi S; Tsurutani J; Kadowaki S; Yamaguchi K; Iwasa S; Saito K; Fujisaki Y; Sugihara M; Shahidi J; Doi T
Lancet Oncol; 2019 Jun; 20(6):827-836. PubMed ID: 31047804
[TBL] [Abstract][Full Text] [Related]
25. Trastuzumab deruxtecan in previously treated HER2-positive metastatic breast cancer: Plain language summary of the DESTINY-Breast01 study.
Modi S
Future Oncol; 2021 Sep; 17(26):3415-3423. PubMed ID: 34263665
[TBL] [Abstract][Full Text] [Related]
26. The effects of T-DXd on the expression of HLA class I and chemokines CXCL9/10/11 in HER2-overexpressing gastric cancer cells.
Nakajima S; Mimura K; Matsumoto T; Thar Min AK; Ito M; Nakano H; Neupane P; Kanke Y; Okayama H; Saito M; Momma T; Watanabe Y; Hanayama H; Hayase S; Saze Z; Kono K
Sci Rep; 2021 Aug; 11(1):16891. PubMed ID: 34413454
[TBL] [Abstract][Full Text] [Related]
27. Optimizing treatment management of trastuzumab deruxtecan in clinical practice of breast cancer.
Rugo HS; Bianchini G; Cortes J; Henning JW; Untch M
ESMO Open; 2022 Aug; 7(4):100553. PubMed ID: 35964548
[TBL] [Abstract][Full Text] [Related]
28. Management of patients with HER2-positive metastatic breast cancer after trastuzumab deruxtecan failure.
Antonarelli G; Corti C; Tarantino P; Salimbeni BT; Zagami P; Marra A; Trapani D; Tolaney S; Cortes J; Curigliano G
ESMO Open; 2023 Aug; 8(4):101608. PubMed ID: 37467660
[TBL] [Abstract][Full Text] [Related]
29. Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low-Expressing Advanced Breast Cancer: Results From a Phase Ib Study.
Modi S; Park H; Murthy RK; Iwata H; Tamura K; Tsurutani J; Moreno-Aspitia A; Doi T; Sagara Y; Redfern C; Krop IE; Lee C; Fujisaki Y; Sugihara M; Zhang L; Shahidi J; Takahashi S
J Clin Oncol; 2020 Jun; 38(17):1887-1896. PubMed ID: 32058843
[TBL] [Abstract][Full Text] [Related]
30. Trastuzumab deruxtecan: An antibody-drug conjugate embracing its destiny in breast cancer.
Makhlin I; DeMichele A
Cell Rep Med; 2022 Jun; 3(6):100668. PubMed ID: 35732147
[TBL] [Abstract][Full Text] [Related]
31. Sacituzumab govitecan and trastuzumab deruxtecan: two new antibody-drug conjugates in the breast cancer treatment landscape.
Adams E; Wildiers H; Neven P; Punie K
ESMO Open; 2021 Aug; 6(4):100204. PubMed ID: 34225076
[TBL] [Abstract][Full Text] [Related]
32. Effect of Trastuzumab Deruxtecan on QT/QTc Interval and Pharmacokinetics in HER2-Positive or HER2-Low Metastatic/Unresectable Breast Cancer.
Shimomura A; Takano T; Takahashi S; Sagara Y; Watanabe J; Tokunaga E; Shinkai T; Kamio T; Kikumori K; Kamiyama E; Fujisaki Y; Saotome D; Yamashita T
Clin Pharmacol Ther; 2023 Jan; 113(1):160-169. PubMed ID: 36164935
[TBL] [Abstract][Full Text] [Related]
33. Patient-reported outcomes and hospitalization data in patients with HER2-positive metastatic breast cancer receiving trastuzumab deruxtecan or trastuzumab emtansine in the phase III DESTINY-Breast03 study.
Curigliano G; Dunton K; Rosenlund M; Janek M; Cathcart J; Liu Y; Fasching PA; Iwata H
Ann Oncol; 2023 Jul; 34(7):569-577. PubMed ID: 37179020
[TBL] [Abstract][Full Text] [Related]
34. Reduction of Tumor Biomarkers from very High to Normal and Extensive Metastatic Lesions to Undetectability in a Patient With Stage IV HER2-positive Breast Cancer Treated With Low-dose Trastuzumab Deruxtecan in Combination With Oral Recombinant Methioninase and a Low-methionine Diet.
Sato M; Han Q; Mori R; Mizuta K; Kang BM; Morinaga S; Kobayashi N; Ichikawa Y; Nakajima A; Hoffman RM
Anticancer Res; 2024 Apr; 44(4):1499-1504. PubMed ID: 38538002
[TBL] [Abstract][Full Text] [Related]
35. DS-8201a, a new HER2-targeting antibody-drug conjugate incorporating a novel DNA topoisomerase I inhibitor, overcomes HER2-positive gastric cancer T-DM1 resistance.
Takegawa N; Nonagase Y; Yonesaka K; Sakai K; Maenishi O; Ogitani Y; Tamura T; Nishio K; Nakagawa K; Tsurutani J
Int J Cancer; 2017 Oct; 141(8):1682-1689. PubMed ID: 28677116
[TBL] [Abstract][Full Text] [Related]
36. Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity.
Ogitani Y; Hagihara K; Oitate M; Naito H; Agatsuma T
Cancer Sci; 2016 Jul; 107(7):1039-46. PubMed ID: 27166974
[TBL] [Abstract][Full Text] [Related]
37. [Fam-] trastuzumab deruxtecan (DS-8201a)-induced antitumor immunity is facilitated by the anti-CTLA-4 antibody in a mouse model.
Iwata TN; Sugihara K; Wada T; Agatsuma T
PLoS One; 2019; 14(10):e0222280. PubMed ID: 31574081
[TBL] [Abstract][Full Text] [Related]
38. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer.
Modi S; Saura C; Yamashita T; Park YH; Kim SB; Tamura K; Andre F; Iwata H; Ito Y; Tsurutani J; Sohn J; Denduluri N; Perrin C; Aogi K; Tokunaga E; Im SA; Lee KS; Hurvitz SA; Cortes J; Lee C; Chen S; Zhang L; Shahidi J; Yver A; Krop I;
N Engl J Med; 2020 Feb; 382(7):610-621. PubMed ID: 31825192
[TBL] [Abstract][Full Text] [Related]
39. The efficacy of sacituzumab govitecan and trastuzumab deruxtecan on stable and active brain metastases in metastatic breast cancer patients-a multicenter real-world analysis.
Dannehl D; Jakob D; Mergel F; Estler A; Engler T; Volmer L; Frevert ML; Matovina S; Englisch A; Tegeler CM; Rohner A; Seller A; Hahn M; Pfister K; Fink A; Popp I; Lorenz S; Tabatabai G; Juhasz-Böss I; Janni W; Brucker S; Taran FA; Hartkopf A; Schäffler H
ESMO Open; 2024 May; 9(5):102995. PubMed ID: 38636292
[TBL] [Abstract][Full Text] [Related]
40. Trastuzumab deruxtecan in previously treated patients with HER2-positive metastatic breast cancer: updated survival results from a phase II trial (DESTINY-Breast01).
Saura C; Modi S; Krop I; Park YH; Kim SB; Tamura K; Iwata H; Tsurutani J; Sohn J; Mathias E; Liu Y; Cathcart J; Singh J; Yamashita T
Ann Oncol; 2024 Mar; 35(3):302-307. PubMed ID: 38092229
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
